Table 1 Summary of studies employing

Study	Cell type	Delivery route	Timing of infusion post-MI	Follow-up period	Follow-up method	Outcome
TOPCARE-AMI [8]	BM-MNCs	Intracoronary	4.3 days	4 months 1 year	LV angiography Dobutamine stress echocardiography FDG-PET	Improvement in LV function
BOOST[11]	BM-MNCs	Intracoronary	4.8 days	6 months 5 years	Cardiac MRI	Improvement in LVEF at 6 months but no appreciable increase in LVEF over 5 years
REPAIR-AMI[13]	BM-MNCs	Intracoronary	4.4 days	4 months 1 year 2 year	LV angiography Cardiac MRI	Greater improvements in LVEF in cell therapy patients vs. control. Less adverse clinical outcomes* in cell therapy group at 4 months, 1 years and 2 years
ASTAMI[15]	BM-MNCs	Intracoronary	6 days	6 months 3 year	SPECT Echocardiography Cardiac MRI Exercise capacity testing	6 month follow-up did not show statistically significant improvements in LVEF, EDSV or infarct size. However, 3 year follow-up revealed improvements in exercise time.
FINCELL[18]	BM-MNCs	Intracoronary	3 days	6 months	LV angiography Echocardiography	Statistically significant improvement in LVEF at 6 months.
REGENT[20]	BM-MNCs vs. CD34+CXCR4+ vs. placebo	Intracoronary	7 days	6 months	LV angiography Cardiac MRI	Modest increases in LVEF were realized in the cell therapy groups over placebo.
BALANCE[21]	BM-MNCs	Intracoronary	7 days	3 months 12 months 60 months	LV angiography	Improved LV contractility and mortality reduction over 3, 12 and 60 months.
Cao et al.[22]	BM-MNCs	Intracoronary	7 days	6 months 4 years	Echocardiography SPECT LV angiography	Statistically significant improvement in LVEF and ESV at both time periods.
HEBE[23]	BM-MNCs vs. PB-MNCs vs. control	Intracoronary	6 days	4 months	Cardiac MRI	No statistically significant changes in LVEF though a post-hoc analysis found that patietnts with initial dilation of the LV benefited as cell therapy prevented further dilation.
Janssens et al.[25]	BM-MNCs	Intracoronary	4 days	4 months	Cardiac MRI	Greater reduction of infarct volumes in cell therapy patients particularly those with larger infarcts. No statistically significant increase in LVEF or LV volumes.

Table 1: Summary of studies employing cell therapy after AMI.

Goto home»